- Home
- VRCA
as 11-19-2025 3:19pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 32.7M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 93.9K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.28 - $13.60 | Next Earning Date: | 11-14-2025 |
| Revenue: | $30,829,000 | Revenue Growth: | 234.73% |
| Revenue Growth (this year): | 332.45% | Revenue Growth (next year): | 12.85% |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
GlobeNewswire
10 days ago
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
MT Newswires
a month ago
Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment
GlobeNewswire
a month ago
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
Simply Wall St.
5 months ago
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic?
GlobeNewswire
6 months ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Thomson Reuters StreetEvents
6 months ago
Q1 2025 Verrica Pharmaceuticals Inc Earnings Call
GuruFocus.com
6 months ago
Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ...
Compare VRCA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.